Institut De Recherches Internationales Servier (i.r.i.s.)

This study is testing a drug called vorasidenib in teenagers aged 12 to 17 who have a slow-growing type of brain tumor (grade 2 astrocytoma or oligodendroglioma) with a specific gene mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how well it works, and how it af…